Format

Send to

Choose Destination
Oncotarget. 2016 May 24;7(21):30453-60. doi: 10.18632/oncotarget.8351.

Comparative profiles of BRAF inhibitors: the paradox index as a predictor of clinical toxicity.

Author information

1
Department of Translational Molecular Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 77030, USA.
2
Department of Dermatology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 77030, USA.
3
Graduate School of Biomedical Sciences, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 77030, USA.

Abstract

BRAF inhibitor (BRAFi) therapy is associated with the induction of neoplasia, most commonly cutaneous squamous cell carcinoma (cuSCC). This toxicity is explained in part by "paradoxical ERK activation," or the hyperactivation of ERK signaling by BRAFi in BRAF wild-type cells. However, the rate of cuSCC induction varies widely among BRAFi. To explore this mechanistically, we profiled paradoxical ERK activation by vemurafenib, dabrafenib, encorafenib (LGX818), and PLX8394, demonstrating that vemurafenib induces ERK activation the greatest, while dabrafenib and encorafenib have higher "paradox indices", defined as the pERK activation EC80 divided by the IC80 against A375, corresponding to wider therapeutic windows for achieving tumor inhibition without paradoxical ERK activation. Our results identify differences in the paradox indices of these compounds as a potential mechanism for the differences in cuSCC induction rates and highlight the utility of using ERK activity as a biomarker for maximizing the clinical utility of BRAFi.

KEYWORDS:

BRAF; melanoma; paradoxical ERK; small molecule inhibitor; squamous cell carcinoma

PMID:
27028853
PMCID:
PMC5058692
DOI:
10.18632/oncotarget.8351
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center